NT$ 13.2
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Acepodia, Inc. is an advanced-stage biotechnology firm focused on pioneering cell-based treatments. The company utilizes its distinctive Antibody Cell Conjugation (ACC) platform technology to innovate therapeutic approaches and address critical unmet needs in oncology. Through this proprietary method, Acepodia engineers novel ACE therapies by precisely attaching tumor-specific antibodies to its specialized immune cells, such as gamma delta 2 T cells. Established in 2017, the company's corporate headquarters are situated in Grand Cayman, Cayman Islands.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Data is available to registered users only